Validation study reveals HPV circulating tumor DNA detects residual disease in locally advanced cervical cancer, indicating high risk of relapse.
(Abstracted from J Clin Oncol 2023;42:431–440 The majority of cervical cancers are caused by human papillomavirus (HPV), and despite treatment with chemoradiation (CRT), up to 40% of patients with locally advanced cervical cancer will relapse. Current prognostic factors are poor predictors of relapse; however, detection of HPV circulating tumor DNA (ctDNA) after CRT may identify those at higher risk of relapse.
No takes yet. Share an insight, caveat, or question.
Han et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: